Relevance of liver‐limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE‐3/AIO KRK0306 trial

E-ISSN： 1097-0215|142|5|1047-1055

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.142, Iss.5, 2018-03, pp. : 1047-1055

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Randomized controlled trial of irinotecan drug‐eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver‐limited metastasis

CANCER, Vol. 121, Iss. 20, 2015-10 ,pp. : 3649-3658

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hepatic Arterial Chemotherapy for Colorectal Cancer Metastatic to the Liver

Oncology, Vol. 59, Iss. 2, 2000-08 ,pp. : 89-97

Karger

Access to resources Recommend Favorite

Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open‐label, single‐arm, noncomparative trial

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 14, Iss. 1, 2018-02 ,pp. : 61-68

John Wiley & Sons Inc

Access to resources Recommend Favorite

Panitumumab-Induced Interstitial Lung Disease in a Case of Metastatic Colorectal Cancer

Oncology Research and Treatment, Vol. 36, Iss. 4, 2013-03 ,pp. : 209-212

Karger

Access to resources Recommend Favorite

Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification

Case Reports in Oncology, Vol. 8, Iss. 1, 2015-02 ,pp. : 83-87

Karger

Access to resources Recommend Favorite